Skip to main content

Table 5 Comparison of patient data from visits in which EGD detected esophagitis (n = 52), respectively did not detect esophagitis (n = 125)

From: Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis

 

Esophagitis

Median (Q1, Q3)

No esophagitis

Median (Q1, Q3)

p*

Age

62 (51, 69.5)

64 (56, 72)

0.086

Disease duration

10 (6, 19)

12 (7, 19)

0.487

mRSS

5 (0, 11.75)

2 (0, 6)

0.002

FVC

93.5 (76.5, 110.8)

99 (84, 108)

0.528

BMI

23.2 (21.6, 25.9)

23.8 (21.1, 28.1)

0.407

Hb

13.6 (12.4, 14.6)

12.9 (11.6, 13.7)

0.006

ESR

18 (8, 28)

16 (10, 28)

0.888

 

n (%)

n (%)

p#

Subset of SSc

Diffuse 13 (26.5)

Limited 36 (73.5)

Diffuse 24 (22)

Limited 85 (78)

0.536

Barrett’s esophagus

9 (17.3)

15 (12)

0.347

Heartburn

32 (64)

62 (50.4)

0.104

Regurgitation

13 (26)

25 (20.3)

0.414

Dysphagia

18 (36)

46 (37.4)

0.863

Vomiting

5 (10)

5 (4.1)

0.129

Esophageal symptoms

40 (81.6)

67 (60.4)

0.008

Stomach symptoms

22 (46.8)

39 (35.5)

0.163

PPI therapy

30 (57.7)

89 (72.4)

0.057

Digital ulcers

9 (27.3)

11 (15.7)

0.217

Joint contractures

16 (33.3)

32 (29.1)

0.594

UCLA GIT 2.0 subscales

Median (Q1, Q3)

Median (Q1, Q3)

p*

Reflux

0.50 (0.25, 0.84)

0.38 (0.13, 0.88)

0.534

Distention/bloating

0.50 (0.06, 1.00)

0.75 (0.25, 1.50)

0.069

Fecal soilage

0.00 (0.00, 0.00)

0.00 (0.00, 1.00)

0.535

Diarrhea

0.00 (0.00, 0.50)

0.00 (0.00, 0.50)

0.708

Social functioning

0.17 (0.00, 0.50)

0.17 (0.00, 0.50)

0.283

Emotional wellbeing

0.00 (0.00, 0.33)

0.11 (0.00, 0.44)

0.337

Constipation

0.00 (0.00, 0.50)

0.25 (0.00, 0.75)

0.404

Total score of UCLA GIT 2.0

0.27 (0.16, 0.61)

0.37 (0.13, 0.74)

0.452

  1. Statistically significant results are highlighted in bold font. *Mann-Whitney U test, #Chi-square test
  2. mRSS modified Rodnan skin score, FVC forced vital capacity, BMI body mass index;, Hb hemoglobin, ESR erythrocyte sedimentation rate, PPI proton pump inhibitors